Margot H Uijterwaal
Overview
Explore the profile of Margot H Uijterwaal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uijterwaal M, van Dijk D, Lok C, de Kroon C, Kasius J, Zweemer R, et al.
Int J Gynecol Cancer
. 2024 Apr;
34(6):847-854.
PMID: 38658021
Objectives: Multiple studies have proven the prognostic value of molecular classification for stage I-III endometrial cancer patients. However, studies on the relevance of molecular classification for stage IV endometrial cancer...
2.
van der Wel A, Uijterwaal M, Aarts J
Ned Tijdschr Geneeskd
. 2021 Dec;
165.
PMID: 34854652
Background: The antigen CA125 is mainly known as a tumour marker in ovarian cancer, but may also be elevated in benign gynaecological disorders and non-gynaecological diseases. Case Description: We examined...
3.
Polman N, Uijterwaal M, Witte B, Berkhof J, van Kemenade F, Spruijt J, et al.
Int J Cancer
. 2016 Sep;
140(2):423-430.
PMID: 27677098
Women treated for high-grade cervical intraepithelial neoplasia (CIN) are at risk of recurrent CIN Grade 2 or worse (rCIN2+). Currently, posttreatment monitoring is performed using cytology or cytology/high-risk (hr)HPV cotesting....
4.
Luttmer R, De Strooper L, Berkhof J, Snijders P, Dijkstra M, Uijterwaal M, et al.
Int J Cancer
. 2015 Aug;
138(4):992-1002.
PMID: 26317579
Recently, DNA methylation analysis of FAM19A4 in cervical scrapes has been shown to adequately detect high-grade cervical intraepithelial neoplasia and cervical cancer (≥ CIN3) in high-risk HPV (hrHPV)-positive women. Here,...
5.
Uijterwaal M, Polman N, van Kemenade F, Van Den Haselkamp S, Witte B, Rijkaart D, et al.
Cancer Prev Res (Phila)
. 2015 Mar;
8(6):502-8.
PMID: 25776933
Primary human papillomavirus (HPV)-based cervical screening will be introduced in the Netherlands in 2016. We assessed the 5-year cervical (pre)cancer risk of women with different combinations of HPV and cytology...
6.
Uijterwaal M, Polman N, Witte B, van Kemenade F, Rijkaart D, Berkhof J, et al.
Int J Cancer
. 2014 Oct;
136(10):2361-8.
PMID: 25345358
Primary human papillomavirus (HPV)-based screening results in a 2-5% lower specificity for cervical intraepithelial neoplasia Grade 2 or worse (CIN2+) compared to Pap cytology. To identify HPV-positive women with CIN2+,...
7.
Uijterwaal M, Kocken M, Berkhof J, Bekkers R, Verheijen R, Helmerhorst T, et al.
J Low Genit Tract Dis
. 2014 Apr;
18(4):338-43.
PMID: 24769656
Objective: Women treated for high-grade cervical disease (cervical intraepithelial neoplasia grade 2 or grade 3 [CIN2/3]) face a significant risk of developing post-treatment disease. Therefore, in most European countries, they...
8.
Uijterwaal M, Verhoef V, Snijders P, Meijer C
Expert Rev Mol Diagn
. 2014 Mar;
14(3):245-8.
PMID: 24598044
Several studies have shown that the human papilloma virus (HPV) test is a more sensitive and objective primary cervical cancer screening tool than cytology. Therefore, conversion of cytology into HPV...
9.
Kocken M, Uijterwaal M, de Vries A, Berkhof J, Ket J, Helmerhorst T, et al.
Gynecol Oncol
. 2012 Jan;
125(2):500-7.
PMID: 22266548
Objective: Currently, women treated for high-grade cervical intraepithelial neoplasia (CIN 2/3) are followed-up by cytology to monitor them for residual and recurrent (post-treatment) disease. This systematic review and meta-analysis determine...